In addition, the paucity of IDH1/2 mutations (1.9%) suggested that metabolic inhibition of TET2 by aberrant 2-HG production was also uncommon in T-ALL (Fig. 1A). The gene discussed is TET2; the disease is acute lymphoblastic leukemia.